Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

652 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Postoperative treatment with docetaxel, cisplatin, and capecitabine (DCX) and chemoradiotherapy (CRT) with capecitabine for resected gastric adenocarcinoma.
Saridaki Z, Lambrodimou G, Kachris S, Makrantonakis P, Boukovinas I, Polyzos A, Anagnostopoulos A, Athanasiadis A, Stoltidis D, Georgoulias V, Souglakos J. Saridaki Z, et al. Among authors: anagnostopoulos a. Am J Clin Oncol. 2015 Feb;38(1):17-22. doi: 10.1097/COC.0b013e3182893f13. Am J Clin Oncol. 2015. PMID: 23563209
Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group.
Linardou H, Aravantinos G, Efstathiou E, Kalofonos C, Anagnostopoulos A, Deliveliotis C, Bafaloukos D, Athanasios Dimopoulos M, Bamias A; Phase II study of Hellenic Co-operative Oncology Group. Linardou H, et al. Among authors: anagnostopoulos a. Urology. 2004 Sep;64(3):479-84. doi: 10.1016/j.urology.2004.04.024. Urology. 2004. PMID: 15351574 Clinical Trial.
Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide.
Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, Zervas K, Tsatalas C, Kokkinis G, Repoussis P, Symeonidis A, Delimpasi S, Katodritou E, Vervessou E, Michali E, Pouli A, Gika D, Vassou A, Terpos E, Anagnostopoulos N, Economopoulos T, Pangalis G. Dimopoulos MA, et al. Among authors: anagnostopoulos n, anagnostopoulos a. J Clin Oncol. 2007 Aug 1;25(22):3344-9. doi: 10.1200/JCO.2007.10.9926. Epub 2007 Jun 18. J Clin Oncol. 2007. PMID: 17577016 Clinical Trial.
Myelotoxicity of oral topotecan in relation to treatment duration and dosage: a phase I study.
Stathopoulos GP, Ardavanis A, Papakotoulas P, Pectasides D, Papadopoulos G, Antoniou D, Athanasiadis A, Trafalis D, Anagnostopoulos A, Koutantos J, Vaslamatzis M. Stathopoulos GP, et al. Among authors: anagnostopoulos a. Anticancer Drugs. 2010 Feb;21(2):202-5. doi: 10.1097/CAD.0b013e3283350092. Anticancer Drugs. 2010. PMID: 20010424 Clinical Trial.
Diagnosis and management of Waldenstrom's macroglobulinemia.
Dimopoulos MA, Kyle RA, Anagnostopoulos A, Treon SP. Dimopoulos MA, et al. Among authors: anagnostopoulos a. J Clin Oncol. 2005 Mar 1;23(7):1564-77. doi: 10.1200/JCO.2005.03.144. J Clin Oncol. 2005. PMID: 15735132 Review.
Extent of damage and repair in the p53 tumor-suppressor gene after treatment of myeloma patients with high-dose melphalan and autologous blood stem-cell transplantation is individualized and may predict clinical outcome.
Dimopoulos MA, Souliotis VL, Anagnostopoulos A, Papadimitriou C, Sfikakis PP. Dimopoulos MA, et al. Among authors: anagnostopoulos a. J Clin Oncol. 2005 Jul 1;23(19):4381-9. doi: 10.1200/JCO.2005.07.385. Epub 2005 May 9. J Clin Oncol. 2005. PMID: 15883412
652 results